Anacor strikes distribution deal with Sandoz; StemCells raises $19M;

@FierceBiotech: Will AbbVie now emerge as the next megamerger target? More | Follow @FierceBiotech

@JohnCFierce: New Science Ventures joins the biotech VC boom, plots $100M fund. News | Follow @JohnCFierce

@DamianFierce: Cutting jobs, ditching "unpromising" R&D programs -- $AGN is slowly becoming the company $VRX wants it to be. Just, you know, minus $VRX. | Follow @DamianFierce

@EmilyMFierce: What?! Update on the Found Vials: There Weren't 6; There Were 327. (Not All of Them Were Smallpox.) More from Wired | Follow @EmilyMFierce

> Anacor Pharmaceuticals struck a deal with Sandoz to distribute and commercialize Anacor's drug Kerydin (tavaborole) topical solution, 5% in the United States. Release

> Newark, CA-based StemCells raised $18.7 million in a stock offering. Release

Medical Device News

@FierceMedDev: Stryker delivers positive Q2 numbers but stays mum on inversion. ICYMI Friday | Follow @FierceMedDev

@MichaelGFierce: Delivering breast cancer drug through the skin grants disease prevention. FierceDrugDelivery article | Follow @MichaelGFierce

@VarunSaxena2: Venture capitalist spending bonanza lifts med tech investment in Q2. Report | Follow @VarunSaxena2

@EmilyWFierce: DC journo raises $75K on Kickstarter to fly drones over factory farms, circumvent "ag-gag" laws. More from NPR | Follow @EmilyWFierce

> MIT device could give arthritics and others a helping hand with extra fingers. Story

> Miss Idaho wears insulin pump in swimsuit competition. Item

> Patient groups argue for faster med tech FDA approvals at industry meeting. Article

Pharma News

@FiercePharma: Tops this weekend: AbbVie finally gets Shire, its low tax base and enough new drugs to protect its future. News | Follow @FiercePharma

@TracyStaton: CVS Caremark lays out case for new specialty-drug pricing approach in JAMA editorial. More | Follow @TracyStaton

@EricPFierce: ICYMI: Teva says it is cooperating with probe by Israel into source of blood infections taking Teva product. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Allergan plotting 1,500 job cuts as part of restructuring. Release | Follow @CarlyHFierce

> Defensive Allergan plots 1,500 job cuts, hikes forecast to fight off Valeant. Article

> Animal health companies not exempt from FDA marketing regs, either. Item

> Roche CEO: No appetite for expensive megadeals here. Story

CRO News

> Amid global expansion, India's GVK focuses on clinical development. Story

> CRO Chiltern snags rival Ockham to bolster its oncology footprint. Report

> Post-buyout Harlan inks a CRO partnership with Fluofarma. Article

> Theorem eyes an Indian expansion with latest partnership. Story

> Catalent shoots for $872M in a blockbuster IPO. News

Biotech IT News

> Google-backed service provider gives clients direct control of robot-run lab. Report

> FDA adds recalls API as openFDA initiative gathers pace. News

> Bioinformatics skills help Codexis strike $25M deal with GSK. Story

> Report: Development IT hit hard in Novartis cutbacks. Article

> Novartis and Google team up to commercialize 'smart' contact lenses. Item

Animal Health News

> Seizures in horses in Kentucky focus attention on drug compounding. More

> Virbac H1 sales hurt by Iverhart recall in U.S. Report

> Sanofi's Merial revives heartworm treatment. Article

> Why is there increased activity in animal health IPOs? Item

> France's AB Science warned by FDA for its canine cancer drug promotion. Story

> Merck prods cattle producers to help it test the safety of withdrawn Zilmax. Article

Suggested Articles

Akero's FGF21 analog beat placebo at reducing liver fat in patients with nonalcoholic steatohepatitis (NASH).

Amgen has become the latest biopharma to try to figure out the hit it may take to its pipeline timings amid the COVID-19 pandemic.

The database was locked at the end of February but will only be unblinded after the FDA has provided feedback.